Silverarc Capital Management, LLC Macrogenics Inc Transaction History

Silverarc Capital Management, LLC

$298 Million
Q1 2024

A detailed history of Silverarc Capital Management, LLC transactions in Macrogenics Inc stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 478,079 shares of MGNX stock, worth $2.03 Million. This represents 2.36% of its overall portfolio holdings.

Number of Shares

478,079

Previous 1,258,641 62.02%

Holding current value

$2.03 Million

Previous $12.1 Million 41.88%

% of portfolio

2.36%

Previous 3.83%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$9.77 - $21.47 $7.63 Million - $16.8 Million	-780,562 Reduced 62.02%	478,079 $7.04 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $24,716 - $55,776	-5,517 Reduced 0.44%	1,258,641 $12.1 Million
Q3 2023 Nov 13, 2023	BUY	$4.48 - $6.19 $217,203 - $300,109	48,483 Added 3.99%	1,264,158 $5.89 Million
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $675,139 - $1.1 Million	-146,134 Reduced 10.73%	1,215,675 $6.5 Million
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $3.61 Million - $5.43 Million	749,334 Added 122.35%	1,361,809 $9.76 Million

Q4 2022 Feb 14, 2023	BUY	$5.62 - $6.98 $2.88 Million - $3.58 Million	512,475 Added 512.48%	612,475 $4.11 Million
Q3 2022 Oct 28, 2022	BUY	$3.01 - $5.22 $301,000 - $522,000	100,000 New	100,000 $346,000
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $3.49 Million - $5.08 Million	-176,915 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $3.62 Million - $6.3 Million	176,915 New	176,915 $4.75 Million

Others Institutions Holding MGNX

# of Institutions

170

Shares Held

62.4M

Call Options Held

819K

Put Options Held

79.4K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $261M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.

Account

Silverarc Capital Management, LLC Macrogenics Inc Transaction History